相关实验视频
Updated: Jun 15, 2025
23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
7.9K
帕金森病治疗中的新策略:一篇综述
Charles L Mitchell1,2, Dmitry Kurouski1,2
1Interdisciplinary Program in Genetics and Genomics, Texas A&M University, College Station, TX, United States.
Frontiers in molecular neuroscience
|August 26, 2024
概括
由于诊断的增加,迫切需要有效的神经保护性治疗帕金森病 (PD). 本综述探讨了先进的疗法,从小分子转向自然降解途径和免疫细胞以清除有毒沉积物.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 预期寿命的增加导致帕金森病 (PD) 诊断的全球增加.
- 目前对PD和阿尔茨海默病 (AD) 的治疗方法可以控制症状,但不能进行神经保护.
- 病发病的经济负担很大,每年估计为520亿美元,这凸显了对有效治疗的需要.
研究的目的:
- 审查治疗帕金森病的先进治疗策略.
- 讨论PD治疗中不断变化的治疗范式.
- 探索超越基于小分子抑制蛋白质聚合的新方法.
主要方法:
- 对PD当前和新兴治疗策略的文献综述.
- 对转向自然降解途径和基于免疫细胞的疗法进行批判性分析.
- 检查了在PD中降解有毒粉样蛋白沉积物的方法.
主要成果:
- 确定PD的先进治疗策略.
- 讨论从蛋白质聚合抑制剂过渡到自然清除机制.
- 突出免疫细胞和自然途径在降解有毒大脑沉积物的潜力.
结论:
- 对帕金森病的神经保护疗法有着显著的未满足的需求.
- 对于PD的治疗方法正在转向利用身体的自然清除机制.
- 免疫细胞和自然降解途径对清除PD患者中有毒的粉样蛋白沉积物充满希望.
相关概念视频
01:24Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
01:15Parkinson's Disease: Overview
500
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
500
01:22Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
01:28Drug Therapy
40
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
40
01:37Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
01:23Antidepressant Drugs: MAOIs and Other Agents
205
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
205